Large genomic rearrangements in the CFTR gene contribute to CBAVD.

Magali Taulan, Anne Girardet, Caroline Guittard, Jean-Pierre Altieri, Carine Templin, Christophe Béroud, Marie Des Georges, Mireille Claustres

To cite this version:
Magali Taulan, Anne Girardet, Caroline Guittard, Jean-Pierre Altieri, Carine Templin, et al.. Large genomic rearrangements in the CFTR gene contribute to CBAVD.. BMC Medical Genetics, BioMed Central, 2007, 8, pp.22. <10.1186/1471-2350-8-22>. <inserm-00305450>
Large genomic rearrangements in the CFTR gene contribute to CBAVD
Magali Taulan1,2,3, Anne Girardet1,2,3, Caroline Guittard3, Jean-Pierre Altieri3, Carine Templin3, Christophe Beroud1,2,3, Marie des Georges1,3 and Mireille Claustres*1,2,3

Address: 1INSERM, U 827, Montpellier, F-34000 France, 2Université Montpellier1, UFR de Médecine, laboratoire de GénétiqueMoléculaire, Montpellier, F-3400 France and 3CHU Montpellier, hôpital Arnaud de Villeneuve, laboratoire de Génétique Moléculaire, Montpellier, F-34000 France

Email: Magali Taulan - magali.taulan@montp.inserm.fr; Anne Girardet - anne.girardet@montp.inserm.fr; Caroline Guittard - caroline.guittard@montp.inserm.fr; Jean-Pierre Altieri - jean-pierre.altieri@montp.inserm.fr; Carine Templin - carine.templin@montp.inserm.fr; Christophe Beroud - christophe.beroud@montp.inserm.fr; Marie des Georges - marie.desgeorges@montp.inserm.fr; Mireille Claustres* - mireille.claustres@montp.inserm.fr

* Corresponding author

Abstract

Background: By performing extensive scanning of whole coding and flanking sequences of the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene, we had previously identified point mutations in 167 out of 182 (91.7%) males with isolated congenital bilateral absence of the vas deferens (CBAVD). Conventional PCR-based methods of mutation analysis do not detect gross DNA lesions. In this study, we looked for large rearrangements within the whole CFTR locus in the 32 CBAVD patients with only one or no mutation.

Methods: We developed a semi-quantitative fluorescent PCR assay (SQF-PCR), which relies on the comparison of the fluorescent profiles of multiplex PCR fragments obtained from different DNA samples. We confirmed the gross alterations by junction fragment amplification and identified their breakpoints by direct sequencing.

Results: We detected two large genomic heterozygous deletions, one encompassing exon 2 (c.54-5811_c.164+2186del8108ins182) [or CFTRdele2], the other removing exons 22 to 24 (c.3964-3890_c.4443+3143del9454ins5) [or CFTRdele 22_24], in two males carrying a typical CBAVD mutation on the other parental CFTR allele. We present the first bioinformatic tool for exon phasing of the CFTR gene, which can help to rename the exons and the nomenclature of small mutations according to international recommendations and to predict the consequence of large rearrangements on the open reading frame.

Conclusion: Identification of large rearrangements further expands the CFTR mutational spectrum in CBAVD and should now be systematically investigated. We have designed a simple test to specifically detect the presence or absence of the two rearrangements identified in this study.
Background
Congenital bilateral absence of the vas deferens (CBAVD) accounts for approximately 3% of cases of male infertility in Caucasian populations. In about 85% of cases, CBAVD is recognized as an autosomal recessive disorder (MIM#277180) associated with mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR, also symbolized ABCC7) [1-3]. Almost all of 1,500 different mutations so far identified in the CFTR gene in cystic fibrosis (CF) (MIM#219700) or in related disorders (updates in the Cystic Fibrosis Mutation Database [4]) are single-nucleotide changes or small base pair(s) insertions or deletions in the exons or their flanking intronic sequences. The CFTR gene encodes a protein expressed in the apical membrane of exocrine epithelial cells which functions principally as a cAMP induced chloride channel and regulates also other ion channels. A combination of severe genetic changes in the two CFTR alleles that reduces CFTR function below 5% of physiological levels usually leads to the severe forms of classical CF [5,6]. Other so-called mild mutations that retain higher CFTR residual function can cause milder or incomplete phenotypes or CFTR-associated phenotypes. CBAVD is caused either by two mild mutations or by a severe and a mild mutation [3,7,8]. Routine testing for the most prevalent mutations in classical CF misses most CFTR gene alterations in the CBAVD phenotype, which can be detected only by scanning the 27 CFTR coding and flanking sequences [8,9]. However, despite exhaustive analysis of the CFTR gene, a proportion of mutations still remains unidentified in CBAVD, ranging from 15 to 40% depending both on the technologies used and the ethnicity of patients.

Recent studies in cases with classical cystic fibrosis suggested that gross rearrangements encompassing a single or several exons could account for a significant part of unidentified alleles. Large deletions have been discovered either fortuitously on the basis of uniparental inheritance of polymorphic markers [10-14] and Southern blotting [15] or through a systematic screening [16-19]. These mutations, when present at the heterozygous state, elude the PCR-based techniques designed to detect small DNA alterations.

In CBAVD, there is paucity of information about large genomic rearrangements and only two have been reported so far but without information on breakpoints sequences [17,20].

In this study, we used a semi-quantitative fluorescent multiplex PCR assay to screen samples from CBAVD patients that remained unresolved after extensive scanning of CFTR exons. Two large deletions have been identified, which further confirms the involvement of gross DNA alterations in CBAVD.

Methods
Nomenclature of mutations
We followed the international nomenclature guidelines recommended in the Human Genome Variation Society web page [21]. However, for convenience to readers used to the nomenclature of the Cystic Fibrosis Mutation Database [4], the usual names of mutations are also indicated [in italic and in brackets].

Recruitment of CBAVD Samples with One or No CFTR mutation
Our current procedure to detect CFTR point mutations responsible for CBAVD includes the following steps: 1) the screening for 33 common CF mutations by using a commercial kit (CF OLA assay, Abbot, Rungis-France), 2) the scanning of all 27 exons and their intronic boundaries by using optimized laboratory DGGE (Denaturing Gradient Gel Electrophoresis) or dHPLC (denaturing High Pressure Liquid phase Chromatography) protocols, 3) the sequencing of any abnormal region to confirm and characterize the sequence change by using ABI Prism BigDye Terminator Cycle Sequencing kit (PE Applied Biosystems). In addition, we also screen DNAs for intronic splicing mutations  c.1679+1634A>G, c.1811+1.6KbA>G and c.3717+10kbC>T using PRC-restriction with appropriate enzymes. The whole procedure has been previously applied to each of the 182 unrelated patients with documented CBAVD who have been referred to our lab so far, allowing us to detect one or two CFTR mutations in 167 of them [8] and unpublished results]. Here we have further studied the 32 samples remaining with one (n = 17) or no (n = 15) mutation. Whenever possible, we studied the familial segregation of mutations and variations in order to determine whether sequence changes were located on a single or on the two parental CFTR alleles. Informed consent to CFTR studies had been previously obtained from patients and relatives at the time of referral.

Search of Gross Rearrangements in the CFTR Gene by SQF-PCR Analysis
We used a semi-quantitative fluorescent multiplex PCR assay (SQF-PCR) developed in our laboratory for the detection of exon deletions and duplications in the CFTR gene. The method relies on the comparison of the fluorescent profiles of multiplex PCR fragments obtained from different samples, the amplification being stopped at the exponential phase. The 27 exons were grouped into three multiplex PCRs with one primer of each pair 5’-labeled with the 6-FAM fluorochrome (oligonucleotide primers available upon request). Amplification mixture included 5 to 20 pmol of each primer and 150 ng of genomic DNA
in a 20 μl volume. Concentration and quality of DNAs were thoroughly determined prior amplification reactions. The PCR cycling conditions were selected using QIAGEN Multiplex PCR Kit according to the manufacturer’s instructions (Qiagen, Courtaboeuf, France). Amplifications were performed with an initial denaturation step at 95°C for 15 min, followed by 20 cycles of 30 s at 95°C denaturation, 90 s at 57°C annealing and 1 min extension at 72°C, followed by a final extension at 72°C for 10 min, using a Gene Amp 9700 Thermal Cycler (Applied Biosystems, Foster City, CA). Amplified DNA fragments were separated on an ABI 310 or 3130xl sequencer at 60°C. Using Genescan and Genotyper (ABI 310) or GeneMapper (ABI 3130xl) softwares, the data were analyzed by superimposing fluorescent profiles of test and control DNAs and by calculating dosage quotient for area and height of all peaks [22] after normalization with an exon of the DMD gene.

**Confirmation of Deletions by Junction Fragment Amplification**

We developed a simple and rapid test to confirm the identified deletions using two distinct duplex PCRs. For mutation c.54-5811_c.164+2186del8108ins182 [CFTRdele2], one pair of primers [23] amplifies wild type exon 2 while the other one has been designed to detect specifically the deleted allele [primers IVS1F (5’-TACACAAGGCTT-GTCTTTAG-3’) and IVS2R (5’GTAAGCCAGATAAT-TCTGC-3’) (this study)]. For mutation c.3964-3890_c.4443+3143del9454ins5 [CFTRdele22_24], we used one pair of primers to amplify wild type exon 22 [23] and primers IVS21-3940F and TAG+3303R [15] to detect the junction fragment of the deletion. PCR products were separated by electrophoresis on a 2% agarose gel and visualized by ethidium bromide staining. This test ensures an internal amplification control and can distinguish between homozygous and heterozygous samples for the deletion.

**Identification of Breakpoints**

We characterized the two large rearrangements by sequencing the amplified fragments of genomic DNA encompassing the breakpoints using primers noted above.

**Computer-Assisted Sequence Analysis**

Large portions of genomic DNA sequences within and around the rearrangements were searched for both low complexity/simple repeats and interspersed repeats using the RepeatMasker program and were analyzed for sequence similarity using the BLAST tool available through UCSC (University of California Santa Cruz) Genome Browser on Human (March 2006 assembly) [24]. To predict the effect of large deletions on the CFTR open reading frame sequences, we used the "exon-phasing tool" of the UMD* software (Universal Mutation Database) [25,26], which gives access to a graphical presentation of all coding exons of a gene according to their phasing in order to predict, at least at the genomic level, the consequence of the deletion of one or more exons on the open reading frame of the CFTR gene.

**Results**

Using a comprehensive CFTR gene analysis protocol we had previously identified CFTR mutations in 167/182 (91.7%) patients with documented CBAVD including 150 (82.4%) with two mutations and 17 (9.3%) with one mutation. In the current study we present the result of our investigations concerning the involvement of large rearrangements in the 32 remaining samples with one or no CFTR small mutation.

**Detection of two Complex CFTR Large Deletions and Confirmation of Deletion Breakpoint Junctions**

Using SQF-PCR, a large genomic deletion was identified in 2 (6.25%) of the 32 samples analyzed in this study. Rearrangement c.54-5811_c.164+2186del8108ins182 [CFTRdele2] (Figure 1A) was found in a 27-year-old patient originating from Southern Italy carrying on the other allele the typical CBAVD splice variant IVS8(TG)12T(5). Rearrangement c.3964-3890_c.4443+3143del9454ins5 [CFTRdele22_24] (Figure 1B) was found in a 41-year-old man with Spanish and Sicily background carrying the missense mutation p.Arg170His. Both large deletions were found to be associated with a 7T allele at the IVS8(7n) locus. The presence of either of the two deletions was confirmed by specific duplex PCRs amplifying both wild-type and deleted alleles in heterozygote samples. DNA sequencing showed that deletions breakpoint junctions appeared to be the same as those recently described in two patients with cystic fibrosis as IVS1-5811_IVS2+2186del8108ins182 [27] or IVS21-3890_Stop+3143del9454ins5 [15].

**Analysis of Genomic Sequences and Exon Phasing of the CFTR Gene**

Despite the presence of Interspersed repeat elements in the vicinity of the rearrangements (Figure 1), there is no significant homology flanking the deletion breakpoints or insertion junctions to suggest that homologous recombination has occurred.

The "exon-phasing tool" of the UMD* software [25] uses a numerotation of CFTR exons in accordance with international nomenclatures and predicts an in-frame deletion of exon 2 (36 amino acids) for mutation c.54-5811_c.164+2186del8108ins182 [CFTRdele2] and the loss of the three last CFTR coding sequences (exons 22 to 24, that should be numbered 25 to 25, totaling 159 amino acids) for mutation c.3964-
A) Confirmation of complex deletion c.54-5811_c.164+2186del8108ins182 [CFTR
dele2] in CBAVD

Figure 1

A) Confirmation of complex deletion c.54-5811_c.164+2186del8108ins182 [CFTR
dele2] in CBAVD. Rearrangement c.54-5811_c.164+2186del8108ins182 (upper panel) consists of a gross deletion of 8108 bp spanning exon 2 (dotted area) and an insertion of 182 bp (grey area) at the deletion junction between the nucleotide 54-5811 of intron 1 (IVS1 nt 18294) and the nucleotide 164+2186 of intron 2 (IVS2 nt 2186) [according to the recommended international nomenclature with the A of the ATG start codon numbered as +1]. The 182-bp insertion is part of intron 3 between IVS3 nucleotides 6780 and 6961 but in inverted orientation (arrow). This complex in/del is also termed c.186-5811_c.296+2186del8108+ins182 with the A of the ATG translation start codon numbered as +133 in accordance with the GenBank reference sequence for the CFTR gene on chromosome 7 (NM_000492.2) and the CF mutation database [4]. It was recently reported as IVS1-5811_IVS2+2186del8108ins182 in one patient with cystic fibrosis [27]. A specifically-designed junction fragment amplification test (lower panel) confirmed the presence of the heterozygous deletion, indicated by specific PCR products on 2% agarose gels (left) by comparison with the non deleted allele. The deletion breakpoint junctions (indicated by vertical bars) and inserted sequences were determined by direct sequencing (right).

B) Confirmation of complex deletion c.3964-3890_c.4443+3143del9454ins5 [CFTRdele22_24 or CFTRdele25_27] in CBAVD. Rearrangement c.3964-3890_c.4443+3143del9454ins5 (upper panel) consists of a gross deletion of 9454 bp (dotted area) encompassing exons 25 to 27 [22 to 24], the stop codon and the poly(A) signal. A small insertion of 5 bases (TAACT) was observed at the junction but is too small to allow any determination of its origin (arrow). The same rearrangement has recently been described in one patient with cystic fibrosis as c.4096-3890_c.4575+3143del9454ins5 with the A of the ATG translation start codon numbered as +133 in accordance with the GenBank reference sequence for the CFTR gene on chromosome 7 (NM_000492.2) or as IVS21-3890Stop+3143del9454insTAACT [15]. A specifically-designed junction fragment amplification test (lower panel) confirmed the presence of the heterozygous deletion, indicated by specific PCR products on 2% agarose gels (left) by comparison with the non deleted allele. The deletion breakpoint junctions (indicated by vertical bars) and inserted sequences were determined by direct sequencing (right).
3890_c.4443+3143del9454ins5 [CFTRdele22_24] (Figure 2).

**Discussion**

Despite the accumulated information about genomic rearrangements in patients with cystic fibrosis, where they account for up to 16 to 24% of CF alleles negative for point mutations in European populations [15-18][27], only two large exonic rearrangements have been described so far in CBAVD [17,20]. The SQF-PCR protocol described in the present study enables the rapid and reliable detection of unknown CFTR gene deletions or duplications in CF or CBAVD. We identified two large rearrangements in two males carrying a typical CBAVD mutation on the other parental CFTR allele in a sample of 32 patients, which elucidates 4.25% of alleles that remained unidentified after standard investigations for point mutations. The remaining unsolved alleles might be explained by mutations in CFTR non-coding regions not explored by genomic DNA-based available methods or by the contribution of other(s) gene(s) to CBAVD. However if we postulate that, for most of the 15 patients with no mutation, CBAVD is probably not linked to CFTR defects, large rearrangements could represent 12% (2/17 alleles) of unidentified alleles, which is in the range of figures observed in the CF population. With this hypothesis, searching for large rearrangements in addition to conventional genotyping would identify two mutations in 152/167 (91%) and one mutation in 15/167 (9%) of CBAVD males. The two deletions found in our CBAVD samples are predicted to be "severe" alleles precluding the production of a functional CFTR protein and are thus null mutations. Bioinformatic analysis of the sequences flanking large rearrangements in the CFTR gene suggest that non-homologous end joining [28] is the most likely mechanism that is responsible for their occurrence, in accordance with recent studies [17,27].

**Conclusion**

Screening for large genomic rearrangements in the CFTR gene is beneficial not only in classical cystic fibrosis but also in CBAVD, especially for those males who are carriers of a CFTR mild mutation. This study strengthens the importance to include screening of gross rearrangements in CFTR mutations scanning to offer adequate diagnosis and genetic counselling for CBAVD couples. International numerotation of exons should be used in order to avoid future misdiagnosis.

**Abbreviations**

CFTR, cystic fibrosis transmembrane conductance regulator  
CBAVD, congenital bilateral absence of the vas deferens  
CF, cystic fibrosis

---

**Figure 2**

Exon phasing of the CFTR gene (Universal Mutation Database [25]). The CFTR gene comprises 27 exons which were previously numbered 1–24 [23] with subdivisions A and B for exons 6, 14 and 17, recognized as distinct units after the initial publication of the gene (GenBank NM_000492.2). Here we presents the numerotation of CFTR exons as described in UCSC (University of California Santa Cruz) Human Genome databases and updated as March 2006 Assembly [24]. Each exon is presented as a blue box with the international numbering within the box, and the familiar numbering above it. Each extremity of the box represents the specific phasing of the exon. **Left end of exons:** 1) vertical extremity: the exon begins by the first nucleotide of a codon; 2) curve: the exon begins by the second nucleotide of a codon; 3) arrow: the exon begins by the third nucleotide of a codon. **Right end of exons:** 1) vertical extremity: the exon ends by the last nucleotide of a codon; 2) light blue curve: the exon ends by the first nucleotide of a codon; 3) arrow: the exon ends by the second nucleotide of a codon. Large-scale deletions can introduce a translational frameshift (and lead to a premature termination codon) when two exons are joined end to end (for example, exons 1 and 4). When two exons in the same phase are joined, it is assumed that no frameshift occurs and that a shorter protein with an internal deletion may be produced.
5. Zielenski J: PCR, polymerase chain reaction SQF-PCR, semi-quantitative fluorescent PCR assay

Competing interests
The author(s) declare that they have no competing interests.

Authors' contributions
MT and AG wrote the manuscript; CG, JPA, CT performed the experimental work; CB designed the CFTR exon phasing tool and participated in the drawing of the figures. MdG and MC supervised the study and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements
We are grateful to VLM (Vaincre la Mucoviscose, France) for continuous support in the study (fellowship of M.T.). We also thank the reviewers for constructive suggestions that improved the article.

References
1. Anguiano A, Oates RD, Amos JA, Dean M, Gerrard B, Stewart C, Maher TA, White MB, Milunsky A: Congenital bilateral absence of the vas deferens: A primarily genetic form of cystic fibrosis. JAMA 1992, 268(13):1794-1797.
2. Chillon M, Casals T, Mericier B, Bassas L, Lissens W, Silber S, Romye MC, Ruiz-Romero J, Verlingue C, Clautres M, et al.: Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 1995, 332(22):1475-1480.
3. Clautres M: Molecular pathology of the CFTR locus in male infertility. Reprod Biomed Online 2005, 10(1):4-11.

4. Cystic Fibrosis Mutation Database [http://www.genet.sickkids.on.ca/cftrdb]
5. Zielenks J: Genotype and phenotype in cystic fibrosis. Respiration 2000, 67(2):117-133.
6. Mickle JE, Cutting GR: Genotype-phenotype relationships in cystic fibrosis. Med Clin North Am 2000, 84(3):597-607.
7. Dork T, Dvoronczak B, Aulehla-Scholtz C, Wieczorek K, Dohm B, Bohm M, Mayerova A, Seydewitz HH, Nieschlag E, Meschede D, Horst J, Pogorzelski A, Bal J, Zekanowsky C, Wagner K, Stuhrmann M, Bauer K, Gitoau K, Le Marechal C, Quere I, Cooper DN, Ferec C: Genomic rearrangements in the CFTR gene: extensive allelic heterogeneity and diverse mutational mechanisms. Hum Mutat 2004, 23(4):343-357.
8. Dork T, Macek M Jr, Mekus F, Tummel B, Ztountzouris J, Casals T, Krebova A, Koudova M, Samkaryowa I, Macek M Sr., Vavrova V, Zemkova D, Ginter E, Petrova NV, Ivaschenko T, Baranov V, Witz M, Pogorzelski A, Bal J, Zekanowsky C, Wagner K, Stuhrmann M, Bauer K, Seydewitz HH, Neumann T, Jakubiczka S: Characterization of a novel 21-kb deletion, CFTRdel2,3(21 kb), in a cystic fibrosis mutation of Slavic origin common in Central and East Europe. Hum Genet 2000, 106(3):259-268.
9. Ferec C, Casals T, Chuzhanova N, Macek M, Bienvenu T, Holubova A, King C, McDevitt T, Castellani C, Farrell PM, Sheridan M, Pantaleo G, Gross genomic rearrangements involving deletions in the CFTR gene: characterization of six new variants from a large cohort of hitherto unidentified cystic fibrosis chromosomes and meta-analysis of the underlying mechanisms. Eur J Hum Genet 2006, 14(2):567-576.
10. Lupski JR, Stankiewicz P: Genomic disorders: molecular mechanisms for rearrangements and conveyed phenotypes. PLoS Genet 2005, 1(6):e49.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2350/8/22/prepub